Gyre Therapeutics Inc. (GYRE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $471.74M
Last updated: Nov 17, 2026 at 11:05 AM ET
Gyre Therapeutics Inc. (GYRE) Earnings: Report Dates and Results
Gyre Therapeutics (GYRE) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Gyre Therapeutics reported EPS of $0.04, above the -$0.15 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
GYRE has an expected report date of Mar 10, 2027.
Earnings History
Of the 16 quarters below that had an estimate, GYRE beat 7 and missed 9. Revenue for the quarter ended Sep 30, 2026 was $32.93M, up 0.7% from $32.69M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.04 | -$0.15 | -$0.19 - -$0.06 | +126.67% | Beat | +33.3% | 3 | 1 up, 2 down | Nov 5, 2026 | $32.93M |
| Jun 30, 2026 | -$0.12 | -$0.08 | -$0.09 - $0.00 | -50.00% | Miss | -5554.5% | 3 | 0 up, 1 down | Aug 7, 2026 | $29.11M |
| Mar 31, 2026 | -$0.10 | -$0.07 | -$0.11 - -$0.04 | -42.86% | Miss | -2425.6% | 3 | 0 up, 2 down | May 7, 2026 | $22.52M |
| Dec 31, 2025 | $0.05 | $0.05 | N/A | +0.21% | Beat | N/A | 1 | 0 up, 1 down | Mar 12, 2026 | $37.20M |
| Sep 30, 2025 | $0.03 | -$0.02 | -$0.02 - -$0.02 | +250.00% | Beat | +129.0% | 1 | 0 up, 0 down | Nov 7, 2025 | $32.69M |
| Jun 30, 2025 | $0.00 | $0.03 | N/A | -92.67% | Miss | -93.5% | N/A | 0 up, 0 down | Aug 11, 2025 | $29.73M |
| Mar 31, 2025 | $0.00 | $0.03 | N/A | -85.67% | Miss | -86.4% | N/A | 0 up, 0 down | May 9, 2025 | $22.06M |
| Dec 31, 2024 | $0.00 | $0.04 | N/A | -102.75% | Miss | N/A | N/A | 0 up, 0 down | Mar 17, 2025 | $27.87M |
| Sep 30, 2024 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2024 | $25.49M |
| Jun 30, 2024 | $0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2024 | $25.23M |
| Mar 31, 2024 | $0.03 | N/A | N/A | N/A | N/A | -78.9% | N/A | 0 up, 0 down | May 9, 2024 | $27.17M |
| Dec 31, 2023 | Not reported | -$0.60 | N/A | N/A | Not reported | N/A | N/A | 0 up, 0 down | Mar 26, 2024 | $27.15M |
| Sep 30, 2023 | -$1.05 | -$0.75 | N/A | -40.00% | Miss | N/A | N/A | N/A | Oct 26, 2023 | $32.04M |
| Jun 30, 2023 | -$1.05 | -$1.05 | N/A | -0.05% | Miss | -104.3% | N/A | N/A | Aug 14, 2023 | $29.33M |
| Mar 31, 2023 | $0.15 | -$0.07 | N/A | +314.29% | Beat | N/A | N/A | N/A | May 15, 2023 | $24.93M |
| Dec 31, 2022 | -$19.05 | -$0.11 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2023 | $101.50M |
| Sep 30, 2022 | -$2.40 | -$0.10 | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2022 | N/A |
| Jun 30, 2022 | $24.60 | -$0.25 | N/A | N/A | N/A | N/A | N/A | N/A | Aug 15, 2022 | N/A |
| Mar 31, 2022 | -$6.90 | -$0.46 | N/A | N/A | N/A | N/A | N/A | N/A | May 9, 2022 | $794000 |
| Dec 31, 2021 | -$9.75 | -$0.59 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2022 | $2.44M |
| Sep 30, 2021 | -$12.00 | -$0.66 | N/A | N/A | N/A | N/A | N/A | N/A | Nov 12, 2021 | $2.30M |
| Jun 30, 2021 | -$9.60 | -$0.70 | N/A | N/A | N/A | N/A | N/A | N/A | Aug 5, 2021 | $1.13M |
| Mar 31, 2021 | -$11.85 | -$0.58 | N/A | N/A | N/A | N/A | N/A | N/A | May 6, 2021 | $1.47M |
| Dec 31, 2020 | -$12.90 | -$0.86 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 4, 2021 | $1.17M |
| Sep 30, 2020 | -$10.95 | -$0.81 | N/A | N/A | N/A | N/A | N/A | N/A | Nov 5, 2020 | $1.75M |
| Jun 30, 2020 | -$14.40 | -$0.86 | N/A | N/A | N/A | N/A | N/A | N/A | Aug 6, 2020 | $1.66M |
| Mar 31, 2020 | -$4.20 | -$0.37 | N/A | N/A | N/A | N/A | N/A | N/A | May 11, 2020 | $16.37M |
| Dec 31, 2019 | -$18.45 | $0.17 | N/A | N/A | N/A | N/A | N/A | N/A | Feb 20, 2020 | N/A |
| Sep 30, 2019 | -$15.90 | -$1.16 | N/A | N/A | N/A | N/A | N/A | N/A | Nov 7, 2019 | N/A |
| Jun 30, 2019 | -$17.25 | -$1.11 | N/A | N/A | N/A | N/A | N/A | N/A | Aug 1, 2019 | N/A |
| Mar 31, 2019 | -$18.90 | -$1.08 | N/A | N/A | N/A | N/A | N/A | N/A | May 2, 2019 | N/A |
| Dec 31, 2018 | -$13.65 | -$0.75 | N/A | N/A | N/A | N/A | N/A | N/A | Mar 8, 2019 | N/A |
| Sep 30, 2018 | -$9.60 | -$0.59 | N/A | N/A | N/A | N/A | N/A | N/A | Nov 1, 2018 | N/A |
| Jun 30, 2018 | -$8.10 | -$0.62 | N/A | N/A | N/A | N/A | N/A | N/A | Aug 2, 2018 | N/A |
| Mar 31, 2018 | -$8.40 | -$0.92 | N/A | -813.04% | Miss | N/A | N/A | N/A | May 3, 2018 | $6000 |
| Dec 31, 2017 | -$1.25 | -$1.53 | N/A | +18.30% | Beat | N/A | N/A | N/A | Mar 19, 2018 | $318000 |
| Sep 30, 2017 | -$20.10 | -$1.32 | N/A | N/A | N/A | N/A | N/A | N/A | Nov 2, 2017 | $318000 |
| Jun 30, 2017 | -$1.52 | -$1.46 | N/A | -4.11% | Miss | N/A | N/A | N/A | Aug 3, 2017 | $111000 |
| Mar 31, 2017 | -$4.57 | -$6.10 | N/A | +25.08% | Beat | N/A | N/A | N/A | May 11, 2017 | $271000 |
| Dec 31, 2016 | -$4.65 | -$5.63 | N/A | +17.41% | Beat | N/A | N/A | N/A | Mar 8, 2017 | $72000 |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.08, within 4 cents of the year before. It was -$165.78 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.08 | N/A |
| Dec 31, 2024 | $0.08 | N/A |
| Dec 31, 2023 | -$1.95 | N/A |
| Dec 31, 2022 | -$3.75 | N/A |
| Dec 31, 2021 | -$43.20 | N/A |
| Dec 31, 2020 | -$42.45 | N/A |
| Dec 31, 2019 | -$70.50 | N/A |
| Dec 31, 2018 | -$39.75 | N/A |
| Dec 31, 2017 | -$27.44 | N/A |
| Dec 31, 2016 | -$165.78 | N/A |
Frequently Asked Questions About GYRE
When is Gyre Therapeutics's next earnings date?
Gyre Therapeutics's next earnings report is expected for Mar 10, 2027.
Did GYRE beat earnings estimates last quarter?
Yes. Gyre Therapeutics reported EPS of $0.04 for the quarter ended Sep 30, 2026, above the -$0.15 estimate, a 126.67% surprise.
What EPS do analysts expect from GYRE next quarter?
The consensus EPS estimate for Gyre Therapeutics for the quarter ending Dec 31, 2026 is -$0.13 from 5 analysts, with estimates from -$0.20 to -$0.05.
How often does GYRE beat earnings estimates?
Gyre Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of +0.37%.
GYRE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors